Company intelligence / Profile preview

RespireRx Pharmaceuticals

Glen Rock, New Jersey, USArespirerx.com ↗

Ownership: Private
Development stage: Other

Overview

RespireRx has completed multiple Phase 1 safety trials and several Phase 2 proof-of-concept studies with its lead AMPAkine compounds demonstrating target engagement in antagonizing opioid-induced respiratory depression. Dronabinol has shown efficacy in reducing symptoms of obstructive sleep apnea in two completed Phase 2 trials. The company’s GABAkine KRM-II-81 has advanced to further preclinical evaluation within the NIH HEAL Initiative.

Therapeutic areas: PsychiatryPulmonologyNeurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

11 assets

cx516

10 more assets in the full pipeline.

Request access →

Partnerships

Shirley Ryan AbilityLab (for SCI trial)Noramco Inc. (development of dronabinol)Cantheon Capital via ResolutionRx Ltd.

Beyond the preview

Go deeper on RespireRx Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RespireRx Pharmaceuticals.

Explore the full profile